Regression of left ventricular hypertrophy after tafamidis therapy in a patient with transthyretin amyloidosis variant-Reference-Cited by-同舟云学术

Regression of left ventricular hypertrophy after tafamidis therapy in a patient with transthyretin amyloidosis variant

Published:2022 Issue:3.4 Volume:69 Page:320-322
ISSN:1343-1420
Container-title:The Journal of Medical Investigation
language:en
Short-container-title:J. Med. Invest.

Author:

Yagi Shusuke¹,Yamazaki Hiromu¹,Kusunose Kenya¹,Osaki Yusuke²,Ise Takayuki¹,Kadota Muneyuki¹,Tserensonom Munkhtsetseg¹,Kawabata Yutaka¹,Hara Tomoya¹,Ueno Rie¹,Saijo Yoshihito¹,Matsuura Tomomi¹,Yamaguchi Koji¹,Yamada Hirotsugu¹,Fukuda Daiju¹,Soeki Takeshi¹,Wakatsuki Tetsuzo¹,Sata Masataka¹

Affiliation:

1. Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan

2. Department of Neurology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan

Publisher

University of Tokushima Faculty of Medicine

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

https://www.jstage.jst.go.jp/article/jmi/69/3.4/69_320/_pdf

Reference5 articles.

1. 1. Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Planté-Bordeneuve V, Lozeron P, Suhr OB, Campistol JM, Conceição IM, Schmidt HH-J, Trigo P, Kelly JW, Labaudinière R, Chan J, Packman J, Wilson A, Grogan DR : Tafamidis for transthyretin familial amyloid polyneuropathy : a randomized, controlled trial. Neurology 79 : 785-92, 2012

2. 2. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C : Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med 379 : 1007-1016, 2018

3. 3. Endo J, Sano M, Izumiya Y, Tsujita K, Nakamura K, Tahara N, Kuwahara K, Inomata T, Ueda M, Sekijima Y, Ando Y, Tsutsui H, Isobe M, Fukuda K : A Statement on the Appropriate Administration of Tafamidis in Patients With Transthyretin Cardiac Amyloidosis. Circ J 84 : 15-17, 2019

4. 4. Brahmanandam V, McGraw S, Mirza O, Desai AA, Farzaneh-Far A : Regression of Cardiac Amyloidosis After Stem Cell Transplantation Assessed by Cardiovascular Magnetic Resonance Imaging. Circulation 129 : 2326-2328, 2014

5. 5. Damy T, Judge DP, Kristen AV, Berthet K, Li H, Aarts J : Cardiac Findings and Events Observed in an Open-Label Clinical Trial of Tafamidis in Patients with non-Val30Met and non-Val122Ile Hereditary Transthyretin Amyloidosis. J Cardiovasc Transl Res 8 : 117-127, 2015

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tafamidis therapy in transthyretin amyloid cardiomyopathy: a narrative review from clinical trials and real-world evidence;The Egyptian Heart Journal;2024-07-10

2. Tafamidis decreased cardiac amyloidosis deposition in patients with Ala97Ser hereditary transthyretin cardiomyopathy: a 12-month follow-up cohort study;Orphanet Journal of Rare Diseases;2023-09-13